University of North Carolina at Chapel Hill | Lineberger Comprehensive Cancer Center

Research site

(Unclaimed)

Location

720 Martin Luther King Junior Boulevard, Chapel Hill, North Carolina, United States of America

Site insights

Top conditions

Top treatments

Pembrolizumab

Cyclophosphamide

Atezolizumab

Nivolumab

Metformin

Trastuzumab

Pertuzumab

Erlotinib

Fludarabine

Levonorgestrel

Parent organization

This site is a part of University of North Carolina at Chapel Hill

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 49 total trials

A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas

The purpose of this study is to test whether giving acalabrutinib is safe and effective in controlling relapsed central nervous system (CNS) lymphoma...

Enrolling

Central Nervous System Lymphoma

Drug: Acalabrutinib

Drug: Isavuconazole

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB)

This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodyspla...

Enrolling

Relapsed/Refractory AML

Myelodysplastic Syndromes

Drug: Venetoclax

Drug: Azacitidine

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemipli...

Enrolling

Melanoma

Drug: Pembrolizumab

Drug: Fianlimab

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

This is a phase 1, single-center, open-label study that enrolls adult subjects with extensive stage lung cancer or stage IV non-small cell lung cance...

Enrolling

Lung Cancer

Non Small Cell Lung Cancer

Biological: iC9.GD2.CAR.IL-15 T Infusion

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the...

Enrolling

Aging

Multiple Myeloma

Drug: Isatuximab

Drug: Dexamethasone

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Endometrial cancer (EC) is the fourth most common cancer in United States women, and alarmingly, the frequency and mortality from EC continues to ris...

Enrolling

Endometrial Cancer

Metastasis

Drug: ONC201

Drug: Atezolizumab

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

This research is being done to determine if early changes on a type of imaging procedure called PET (Positron Emission Tomography) can predict which...

Active, not recruiting

Breast Cancer

Drug: Pertuzumab

Drug: Trastuzumab

Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors

This first-in-human open-label, dose escalation study is designed to evaluate the safety, tolerability, and PK of MRX-2843 in subjects with relapsed/...

Active, not recruiting

Metastatic Cancer

Advanced Cancer

Drug: MRX-2843

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethas...

Enrolling

Diffuse Large B-cell Lymphoma

Drug: Hyaluronidase

Drug: Dexamethasone

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surg...

Enrolling

Triple Negative Breast Cancer

Drug: Capecitabine

Drug: Sacituzumab govitecan-hziy (SG)

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harb...

Enrolling

Multiple Myeloma

Advanced Solid Tumors

Drug: Trastuzumab and Pertuzumab

Drug: Palbociclib

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulix...

Enrolling

Melanoma

Tumor, Solid

Drug: Palbociclib

Drug: Ulixertinib

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

This is an open-label, window of opportunity platform study for subjects with muscle-invasive bladder cancer (MIBC) who are deemed ineligible or refu...

Active, not recruiting

Bladder Cancer

Drug: Entinostat

Drug: Pembrolizumab